Drug
Batoprotafib clinical trials
Also written TNO155.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Adagrasib (1) · Nazartinib (1) · Rineterkib (1) · Trametinib (1) · Naporafenib (1) · Spartalizumab (1) · Tislelizumab (1)
Studies
Open first, then newest update. How each study uses batoprotafib is read from its arms, and is right about nine times in ten.
Testing it · 5
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedPhase 1Novartis PharmaceuticalsNCT03114319Written as TNO155
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedPhase 1Novartis PharmaceuticalsNCT04294160Written as TNO155
- Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedPhase 1Mirati Therapeutics Inc.NCT04330664Written as TNO155
- Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy ParticipantsWithdrawnPhase 1Novartis PharmaceuticalsNCT05490030Written as TNO155
- Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy ParticipantsWithdrawnPhase 1Novartis PharmaceuticalsNCT05541159Written as TNO155
Given in every arm · 5 — batoprotafib is usual care beside what is tested
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT07468071Written as TNO155
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT04699188Written as TNO155
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as TNO155
- Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedPhase 1Novartis PharmaceuticalsNCT04000529Written as TNO155
- Lorlatinib Combinations in Lung CancerStatus unknownPhase 1/2Massachusetts General HospitalNCT04292119Written as TNO155
Codes
What other systems call batoprotafib · ClinicalTrials.gg INT016583
- UNII (FDA) FPJWORQEGIBATOPROTAFIBConfirmed FDA, Wikidata
- Wikidata Q133821370batoprotafibConfirmed FDA, Wikidata
- NCI Thesaurus C139559BatoprotafibOne source FDA
- DrugBank DB19137One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FPJWORQEGI | BATOPROTAFIB | Confirmed FDA, Wikidata |
| Wikidata | Q133821370 | batoprotafib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C139559 | Batoprotafib | One source FDA |
| DrugBank | DB19137 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.